Susan O'Brien Selected Research

BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)

1/2020	Long-term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia.
1/2020	Long-term results of frontline dasatinib in chronic myeloid leukemia.
5/2019	Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
1/2019	Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs.
11/2018	A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors.
6/2018	Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutations.
11/2017	Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
1/2017	Phase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia.
3/2016	Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction.
11/2015	Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Susan O'Brien Research Topics

Disease

129	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2022 - 02/2002
123	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2020 - 03/2002
78	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2021 - 01/2002
63	Philadelphia Chromosome 01/2021 - 04/2002
61	Neoplasms (Cancer) 01/2022 - 02/2002
55	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 09/2017 - 01/2002
46	Leukemia 01/2018 - 03/2002
40	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 06/2015 - 01/2002
20	Infections 11/2021 - 01/2002
18	Residual Neoplasm 01/2020 - 01/2003
17	Blast Crisis (Blast Phase) 01/2020 - 05/2002
16	Lymphoma (Lymphomas) 01/2019 - 02/2002
16	Hematologic Neoplasms (Hematological Malignancy) 11/2018 - 01/2002
15	Disease Progression 01/2022 - 06/2005
14	Diarrhea 01/2019 - 08/2002
12	Acute Promyelocytic Leukemia 01/2017 - 06/2002
10	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 01/2022 - 02/2002
10	Anemia 01/2018 - 03/2002
9	Lymphocytosis 01/2020 - 09/2006
9	Primary Myelofibrosis (Myelosclerosis) 02/2017 - 09/2002
9	Chronic Myelomonocytic Leukemia (Leukemia, Chronic Myelomonocytic) 04/2014 - 06/2003
8	Hypertension (High Blood Pressure) 12/2019 - 11/2015
8	Thrombocytopenia (Thrombopenia) 01/2019 - 09/2002
8	Pathologic Complete Response 12/2018 - 06/2002
8	Neutropenia 11/2018 - 06/2003
8	Chromosome Aberrations (Chromosome Abnormalities) 07/2014 - 08/2002
7	Atrial Fibrillation 11/2021 - 01/2016
7	Nausea 09/2018 - 12/2003
7	Cytopenia 03/2017 - 11/2007
6	Non-Hodgkin Lymphoma (Lymphosarcoma) 11/2019 - 01/2014
6	Hemorrhage 12/2018 - 06/2009
6	Fatigue 12/2018 - 06/2003
6	B-Cell Lymphoma (Lymphoma, B Cell) 11/2016 - 02/2002
6	Splenomegaly 10/2011 - 03/2002
5	Exanthema (Rash) 01/2020 - 06/2009
5	Second Primary Neoplasms (Neoplasms, Second) 05/2019 - 03/2007
5	Leukocytosis (Pleocytosis) 01/2017 - 12/2003
5	Trisomy (Trisomies) 07/2015 - 08/2002
5	Burkitt Lymphoma (Burkitt's Lymphoma) 06/2015 - 03/2002
5	Lymphadenopathy 12/2014 - 01/2004
5	Hairy Cell Leukemia 10/2011 - 09/2002
5	Myeloproliferative Disorders (Myeloproliferative Disorder) 06/2008 - 09/2002
4	Pneumonia (Pneumonitis) 01/2019 - 01/2016
4	Hyperglycemia 01/2019 - 09/2006

Drug/Important Bio-Agent (IBA)

88	Imatinib Mesylate (Gleevec)FDA Link 01/2018 - 05/2002
48	ibrutinibIBA 01/2022 - 02/2012
48	Tyrosine Kinase InhibitorsIBA 01/2021 - 09/2003
42	Rituximab (Mabthera)FDA Link 12/2021 - 02/2002
35	Cytarabine (Cytosar-U)FDA LinkGeneric 04/2018 - 03/2002
33	fludarabineIBA 12/2021 - 10/2002
32	Monoclonal AntibodiesIBA 11/2019 - 02/2002
28	Cyclophosphamide (Cytoxan)FDA LinkGeneric 12/2021 - 01/2002
23	Agammaglobulinaemia Tyrosine KinaseIBA 01/2022 - 02/2012
23	Dasatinib (BMS 354825)FDA Link 01/2020 - 06/2006
18	Proteins (Proteins, Gene)FDA Link 11/2019 - 03/2002
18	Vincristine (Oncovin)FDA LinkGeneric 12/2018 - 01/2002
17	Inotuzumab OzogamicinIBA 01/2021 - 06/2013
15	nilotinib FDA Link 01/2020 - 06/2006
15	Alemtuzumab (Campath)FDA Link 08/2011 - 05/2003
14	Phosphotransferases (Kinase)IBA 06/2018 - 12/2003
14	Pharmaceutical PreparationsIBA 10/2017 - 02/2002
13	Dexamethasone (Maxidex)FDA LinkGeneric 05/2015 - 01/2002
13	Interferon-alpha (Interferon Alfa)IBA 06/2012 - 04/2002
12	InterferonsIBA 06/2012 - 06/2003
11	Idarubicin (4 Demethoxydaunorubicin)FDA LinkGeneric 01/2017 - 06/2002
11	Doxorubicin (Adriamycin)FDA LinkGeneric 05/2015 - 01/2002
10	Decitabine FDA Link 03/2015 - 08/2003
9	Biological ProductsIBA 01/2018 - 08/2002
9	Tretinoin (Retinoic Acid)FDA LinkGeneric 01/2017 - 06/2002
8	Transaminases (Aminotransferases)IBA 12/2020 - 04/2012
8	Gemtuzumab (Mylotarg)FDA Link 01/2017 - 01/2002
8	Clofarabine (Clolar)FDA Link 06/2014 - 03/2003
7	BilirubinIBA 01/2020 - 04/2012
7	Hemoglobins (Hemoglobin)IBA 02/2014 - 04/2002
7	bcr-abl Fusion ProteinsIBA 01/2008 - 07/2002
6	idelalisibIBA 12/2020 - 09/2011
6	ponatinibIBA 01/2019 - 04/2015
6	Arsenic Trioxide (Trisenox)FDA Link 01/2017 - 05/2003
6	LigandsIBA 07/2015 - 04/2003
6	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 06/2015 - 07/2008
6	NucleosidesIBA 06/2014 - 12/2003
6	Messenger RNA (mRNA)IBA 12/2011 - 02/2007
6	Alkylating AgentsIBA 07/2009 - 01/2004
5	acalabrutinibIBA 11/2021 - 01/2016
5	ofatumumab FDA Link 12/2018 - 10/2010
5	HomoharringtonineIBA 01/2017 - 04/2002
5	Biomarkers (Surrogate Marker)IBA 12/2015 - 02/2010
5	Methotrexate (Mexate)FDA LinkGeneric 02/2015 - 03/2002
5	Erythropoietin FDA Link 11/2010 - 04/2002
5	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 02/2009 - 03/2002
5	TransferasesIBA 11/2007 - 03/2003
4	venetoclaxIBA 01/2018 - 12/2015
4	Phosphatidylinositols (Phosphatidylinositol)IBA 01/2018 - 09/2011
4	Core Binding Factors (Core-Binding Factor)IBA 09/2017 - 07/2009
4	Lenalidomide (CC 5013)FDA Link 01/2016 - 11/2009

Therapy/Procedure

186	Therapeutics 01/2022 - 03/2002
57	Drug Therapy (Chemotherapy) 01/2021 - 01/2002
14	Salvage Therapy 01/2021 - 08/2005
12	Stem Cell Transplantation 02/2018 - 09/2002
4	Transplantation 12/2016 - 05/2007